Influenza vaccine demonstrates favourable immunogenicity and tolerability in clinical testing

Singapore's Agency for Science, Technology and Research and Switzerland's Cytos Biotechnology AG today announced that their influenza vaccine met its primary endpoint for immunogenicity in the Phase 1 clinical trial in healthy Asian volunteers.

http://ift.tt/1mWY048